Patient baseline characteristics
| . | PMBCL, n (%) . | DLBCL, NOS n (%) . | P . |
|---|---|---|---|
| No. of patients | 13 | 131 | — |
| Age, y median (range) | 39 (20-48) | 60 (20-83) | <.0001 |
| Sex, female | 6 of 13 (46) | 34 of 130 (26) | ns |
| Performance status ≥ 2 (ECOG) | 2 of 11 (18) | 16 of 102 (16) | ns |
| Prior therapy lines median (range) | 3 (2-4) | 3 (2-8) | ns |
| Prior auto-HSCT | 0 of 11 | 29 of 125 (23) | ns |
| Prior allo-HSCT | 0 of 11 | 6 of 125 (5) | ns |
| Prior checkpoint inhibition | 2 of 11 (18) | 2 of 122 (2) | .034 |
| Prior radiotherapy | 2 of 11 (18) | 29 of 122 (24) | ns |
| IPI unfavorable (high-intermediate or high) | 6 of 13 (46) | 61 of 123 (48) | ns |
| Refractory disease (refractory against any line of treatment) | 12 of 13 (92) | 108 of 131 (82) | ns |
| LDH elevated∗ | 7 of 13 (54) | 86 of 131 (66) | ns |
| Advanced Ann Arbor stage∗ (III/IV) | 9 of 12 (75) | 88 of 127 (69) | ns |
| Active disease∗ (SD/PD) | 12 of 13 (92) | 112 of 130 (86) | ns |
| Bridging† | ns | ||
| None | 5 of 13 (38) | 34 of 130 (26) | |
| Successful (CR/PR) | 1 of 13 (8) | 19 of 130 (15) | |
| Unsuccessful (SD/PD) | 7 of 13 (54) | 77 of 130 (59) |
| . | PMBCL, n (%) . | DLBCL, NOS n (%) . | P . |
|---|---|---|---|
| No. of patients | 13 | 131 | — |
| Age, y median (range) | 39 (20-48) | 60 (20-83) | <.0001 |
| Sex, female | 6 of 13 (46) | 34 of 130 (26) | ns |
| Performance status ≥ 2 (ECOG) | 2 of 11 (18) | 16 of 102 (16) | ns |
| Prior therapy lines median (range) | 3 (2-4) | 3 (2-8) | ns |
| Prior auto-HSCT | 0 of 11 | 29 of 125 (23) | ns |
| Prior allo-HSCT | 0 of 11 | 6 of 125 (5) | ns |
| Prior checkpoint inhibition | 2 of 11 (18) | 2 of 122 (2) | .034 |
| Prior radiotherapy | 2 of 11 (18) | 29 of 122 (24) | ns |
| IPI unfavorable (high-intermediate or high) | 6 of 13 (46) | 61 of 123 (48) | ns |
| Refractory disease (refractory against any line of treatment) | 12 of 13 (92) | 108 of 131 (82) | ns |
| LDH elevated∗ | 7 of 13 (54) | 86 of 131 (66) | ns |
| Advanced Ann Arbor stage∗ (III/IV) | 9 of 12 (75) | 88 of 127 (69) | ns |
| Active disease∗ (SD/PD) | 12 of 13 (92) | 112 of 130 (86) | ns |
| Bridging† | ns | ||
| None | 5 of 13 (38) | 34 of 130 (26) | |
| Successful (CR/PR) | 1 of 13 (8) | 19 of 130 (15) | |
| Unsuccessful (SD/PD) | 7 of 13 (54) | 77 of 130 (59) |
P < .05 indicates statistical significance.
Allo-HSCT, allogeneic hematopoietic stem cell transplantation; auto-HSCT, autologous hematopoietic stem cell transplantation; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; LDH, lactate dehydrogenase; NOS, not otherwise specified; ns, not significant; PD, progressive disease; PR, partial remission; PS, performance status; SD, stable disease.
Assessed at lymphodepletion.
Bridging was immunotherapy based in the majority of patients who underwent bridging (n = 5 [63%]: brentuximab vedotin, n = 1; rituximab, n = 1; BV-lenalidomide–radiotherapy, n = 1; R-polatuzumab vedotin, n = 1; and pembrolizumab, n = 1). Chemoimmunotherapy was used in 25% of patients who underwent bridging (n = 2: R-BEAM, n = 1; R-GemOx, n = 1). The remaining patient received radiotherapy only.